Integral Health Asset Management LLC Purchases Shares of 150,000 TG Therapeutics, Inc. (NASDAQ:TGTX)

Integral Health Asset Management LLC purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 150,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,515,000. Integral Health Asset Management LLC owned 0.10% of TG Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in TGTX. Bleakley Financial Group LLC acquired a new position in shares of TG Therapeutics during the 4th quarter valued at $245,000. Castellan Group acquired a new position in shares of TG Therapeutics during the 4th quarter valued at $8,539,000. Barclays PLC lifted its holdings in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after acquiring an additional 158,323 shares in the last quarter. Stratos Wealth Advisors LLC acquired a new position in shares of TG Therapeutics during the 4th quarter valued at $241,000. Finally, Strategic Financial Concepts LLC acquired a new position in shares of TG Therapeutics during the 4th quarter valued at $1,404,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Down 0.6%

Shares of NASDAQ:TGTX opened at $33.64 on Monday. The company has a 50 day moving average of $38.90 and a 200-day moving average of $33.70. The firm has a market cap of $5.34 billion, a P/E ratio of -336.37 and a beta of 2.21. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same period in the prior year, the company earned ($0.07) earnings per share. The firm’s revenue for the quarter was up 90.4% on a year-over-year basis. As a group, analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.